Update to living WHO guideline on drugs for covid-19BMJ 2023; 383 doi: https://doi.org/10.1136/bmj.p2622 (Published 09 November 2023) Cite this as: BMJ 2023;383:p2622
This living guideline by Agarwal and colleagues (BMJ 2020;370:m3379) has been updated. For the latest update, visit doi:10.1136/bmj.m3379. The latest version of this WHO living guidance has the following changes:
Recommendations are now ordered by severity of covid-19, and patients stratified into those at low, moderate, or high risk for hospitalisation. New recommendations were added for moderate risk of hospitalisation for nirmatrelvir/ritonavir, and for moderate and low risk of hospitalisation for molnupiravir and remdesivir. New evidence was included for nirmatrelvir/ritonavir and molnupiravir, supporting existing recommendations for patients at high risk of hospitalisation. The recommendation against ivermectin was updated with additional trial evidence. A new recommendation was made against the antiviral agent VV116.